Differences in the clinical characteristics of papillary thyroid microcarcinoma located in the isthmus ≤5 mm and >5 mm in diameter

Feng Zhu, Lixian Zhu, Yibin Shen, Fuqiang Li, Xiaojun Xie and Yijun Wu*

The Department of Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Background: The optimal treatment of papillary thyroid microcarcinomas (PTMCs) located in the isthmus (iPTMCs) is still controversial. The purpose of this study was to compare the clinicopathologic features of patients with iPTMCs ≤5 mm and >5 mm in diameter after total thyroidectomy, and to identify the risk factors for recurrence in patients with iPTMCs.

Methods: A total of 102 iPTMC patients who underwent total thyroidectomy were reviewed retrospectively. The clinicopathologic characteristics of iPTMCs ≤5 mm group (n = 29) have been compared with a group >5 mm (n = 73). Univariate and multivariate Cox proportional hazard models served to identify risk factors associated with recurrence-free survival (RFS).

Results: Gender (p = 0.033), multifocality (p = 0.041), and central lymph node metastasis (CLNM) (p = 0.009) of patients in the ≤5 mm and >5 mm groups differed significantly. iPTMC patients with age <55 years, male, multiple tumor, and extrathyroidal extension showed comparatively more frequent of CLNM in >5 mm groups. Of the 102 patients, nine (8.8%) developed recurrence during follow-up (median: 49.5 months). The patients with recurrences had comparatively high rates of CLNM (p = 0.038), extranodal invasion (p = 0.018), and more MNCND (Metastasis Nodes for Central Neck dissection) (p = 0.020). A cutoff of MNCND >2.46 was established as the most sensitive and specific level for the prediction of recurrence based on receiver operating characteristic (ROC) curve analyses. Multivariate analysis showed that the number of MNCND ≥3 was an independent predictor of poor RFS (p = 0.028).

Conclusion: We have found that the recurrence rates are similar in patients with iPTMCs ≤5 mm and >5 mm. The iPTMCs >5 mm were more likely to be associated with pathological features such as multifocality and CLNM. The male gender, extrathyroidal extension, and CLNM were associated with recurrence of iPTMCs except for tumor size and multifocality. Higher risk of CLNM should be considered in iPTMC >5 mm when it reaches some risk...
patients with iPTMCs evaluate the clinicopathologic characteristics and recurrence rates in PTMC ≤5 mm and >5 mm who underwent total thyroidectomy and bilateral central neck dissection between January 2015 and January 2020 in the Department of Thyroid Surgery of the First Affiliated Hospital, School of Medicine, Zhejiang University were analyzed retrospectively. Before surgery, each patient underwent ultrasound-guided fine-needle aspiration biopsy (FNAB). iPTMC was defined as a PTC located in the isthmus less than 1 cm in size according to final pathologic reports. The clinicopathological data of iPTMC patients were analyzed. These patients were classified into two groups: iPTMC ≤5 mm \((n = 29)\) and iPTMC >5 mm \((n = 73)\). This retrospective study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University. Written informed consent was obtained from all patients before the study.

The iPTMC patients in the study met the following inclusion criteria: the center of the tumor located between two imaginary lines perpendicular to the surface of the skin from the most lateral points of the trachea. Patients who underwent unilateral lobectomy or isthmectomy, secondary surgery, and other types of thyroid cancer were excluded. iPTMCs less than 3 mm were also excluded due to the difficulty of preoperative identification. The 8th edition of the American Joint Committee on cancer (AJCC), TNM classification of malignant tumors in 2016 was used to describe and categorize cancer stages. Radio-iodine therapy was not performed postoperatively. All patients received thyroid-stimulating hormone-suppressive therapy after surgery. Postsurgical physical examinations were performed every 3 to 6 months. The mean follow-up period was 45.2 ± 18.0 months (median: 49.5 months). Cervical CT and FNAB were performed during a follow-up to evaluate suspected recurrences. Reoperation was performed on patients’ suspected recurrence, and postoperative pathology was confirmed.

### Statistical analysis

Statistical analyses were performed using SPSS version 22.0 (SPSS, Chicago, IL). The results were expressed as mean ± SD. Differences between categorical variables were assessed using the Chi-square test or Fisher exact test and continuous variables using Student’s \(t\)-test. Multivariate recurrence analysis was performed using Student’s \(t\)-test. Multivariate recurrence analysis was performed using Student’s \(t\)-test. Multivariate recurrence analysis was performed using Student’s \(t\)-test. Multivariate recurrence analysis was performed using Student’s \(t\)-test. Multivariate recurrence analysis was performed using Student’s \(t\)-test.
conducted using the Cox proportional hazards regression to identify independent prognostic factors. The restricted mean survival time (RMST) was used for survival analysis of variables of CLMN, CLNM ratio, and MNCND, which were not suitable for log-rank test. The time for calculating the RMSTs was set at $t^* = 60$ months. Statistical analysis for cutoff point was assessed by time-dependent ROC curves and was performed using R version 4.2.0 (R Core Team (2022), R Foundation for Statistical Computing, Vienna, Austria), applying the package time ROC for time-dependent ROC analysis. The optimal cutoff point was selected as the closest to (0.1) the criteria. RFS was conducted between the different groups using the Kaplan–Meier analysis, and the differences in curves for each variable were determined by the log-rank test. Results were reported as hazard ratios (HRs) and 95% confidence intervals (95% CI). Differences with $P < 0.05$ were defined as statistically significant.

**Results**

This study included 102 patients of mean age 42.38 ± 11.38 years (range: 22–77 years). The clinicopathologic features of the two groups are shown in Table 1. There were no significant differences in age, thyroglobulin, and thyroidperoxidase antibodies between the ≤5 mm and >5 mm groups at the time of diagnosis. The mean size of the largest tumor was 4.5 ± 0.69 mm in the ≤5 mm group and 7.8 ± 1.43 mm in the >5 mm group. The rate of female patients in the two groups were 93.1% and 75.3%, respectively ($P = 0.033$). The rates of multifocality ($5 (17.2\%)$ vs. $27 (37.0\%); p = 0.041$) and CLNM ($7 (24.1\%)$ vs. $38 (52.1\%); p = 0.009$) were significantly lower in the ≤5 mm than in the >5 mm group. However, there were no statistically significant differences in extrathyroidal extension, TNM stage, and recurrence ($p = 0.442$, $p = 0.526$, and $p = 0.733$, respectively). N1a and N1b classifications were observed in 24.1% and 0% in the ≤5 mm group and in 47.9% and 4.1% in the >5 mm group ($p = 0.031$).

While CLNM was more frequent in patients with <55 years (58.7% vs. 10.0%, $P = 0.004$), male gender (77.8% vs. 43.6%, $P = 0.011$), multifocality tumor (66.7% vs. 43.5%, $P = 0.047$), and extrathyroidal extension (72.2% vs. 45.5%, $P = 0.043$) in >5 mm group, there were no statistically significant differences in ≤5 mm group (<55 vs. ≥55, $P = 0.121$; male vs. female, $P = 0.376$; single vs. multifocality tumor, $P = 0.362$; extrathyroidal extension present vs. absent, $P = 0.554$) (Table 2).

During the follow-up period, nine (8.8%) patients developed recurrence. Table 3 summarizes the nine patients who experienced tumor recurrence. The mean time to recurrence after surgery was 20.2 months (range: 2–50 months). Of these recurrences, the rate of CLNM, multifocality, and extrathyroidal extension was 88.9%, 44.4%, and 55.5%, respectively. All relapsed patients had lateral neck compartment metastases and seven (77.8%) were ipsilateral level III lymph node metastasis. Reoperative surgery was performed in patients with tumor recurrence.

When the nine patients with recurrence were compared with the 93 patients without recurrence in terms of their clinicopathological variables, they were found to be more likely male ($P = 0.049$) and to have higher numbers of extrathyroidal

---

**Table 1** Clinical characteristics of patients with papillary thyroid microcarcinoma located in the isthmus by size.

| Variables                        | ≤5 mm group (n=29) | >5 mm group (n=73) | p value |
|----------------------------------|--------------------|--------------------|---------|
| Age (mean±SD, years)             | 45.0±11.5          | 41.4±11.3          | 0.150   |
| <55                              | 23 (79.3%)         | 63 (86.3%)         |         |
| ≥55                              | 6 (20.7%)          | 10 (13.7%)         | 0.277   |
| No. of females, n (%)            | 27 (93.1%)         | 55 (75.3%)         | 0.033   |
| Size of tumor, mm                | 4.5±0.69           | 7.8±1.43           |         |
| Multifocality,n (%)              | 5 (17.2%)          | 27 (37.0%)         | 0.041   |
| Extrathyroidal extension,n (%)   | 6 (20.7%)          | 18 (24.7%)         | 0.442   |
| CLNM,n (%)                       | 7 (24.1%)          | 38 (52.1%)         | 0.009   |
| Mean no. dissected nodes for CND | 6.1±4.23 (1-20)    | 7.9±5.58 (1-27)    | 0.118   |
| Mean no. metastasis nodes for CND| 0.32±0.61 (0-2)    | 1.9±3.0 (0-14)     | 0.006   |
| N classification (N0/N1a/N1b)    | 22/7/0             | 35/35/3            | 0.031   |
| TNM stage (I/II)                 | 29/0               | 72/1               | 0.526   |
| Recurrence,n (%)                 | 3 (10.3%)          | 6 (8.2%)           | 0.733   |
| TG( mean±SD, ng/mL)              | 24.5±43.4          | 37.6±94.7          | 0.254   |
| TPOAb( mean±SD, IU/mL)           | 304.1±1233.3       | 339.9±878.8        | 0.996   |

CLNM, Central lymph node metastases; CND, Central neck dissection; TG, Thyroglobulin; TPOAb, Thyroid peroxidase antibody.
extension ($p = 0.018$), higher numbers of CLNM ($p = 0.038$), and positive lymph nodes ($p = 0.020$; Table 4). ROC curve was performed to assess the recurrence based on the numbers of lymph nodes metastases ($p = 0.038$), which indicated that the numbers of lymph nodes metastases could accurately predict recurrence in iPTMCs. According to Youden’s index, the best cutoff value was 2.46. The sensitivity and specificity was 55.6% and 86.0%, respectively. Univariate analysis revealed that extrathyroidal extension and MNCND ≥ 3 associated significantly with poor RFS ($p = 0.028$ and $p = 0.008$, respectively). Multivariate analysis showed that MNCND ≥ 3 remained an independent variable for poor RFS (HR = 4.566 [95% CI 1.181–17.657]; $p = 0.028$) (Table 5).

Figure 2 shows the Kaplan–Meier estimates of RFS in iPTMC patients. Tumor size ≤ 5 mm patients did not have statistical differences for recurrence ($p = 0.711$, HR: 0.771, 95% CI: 0.193–3.088; Figure 2A). Compared with the extrathyroidal extension(-) group, the extrathyroidal extension(+) group had significantly lower RFS ($p = 0.017$, HR: 4.359, 95% CI: 1.17–16.25; Figure 2B). Time-dependent ROC analysis was conducted to clarify the best cutoff point of age and rate of CLNM. The cutoff points of age and CLNM ratio were 42 years and 0.111, respectively. CLNM(+) and CLNM ratio >0.111 was significantly related to the lower RFS ($p = 0.035$, RMST (CLNM[+]): 53.15m, 95% CI: 48.41–57.89, RMST(CLNM[−]): 58.69 m, 95% CI: 56.65–60.74, HR=4.886; $p = 0.024$, RMST (CLNM ratio >0.111): 52.42m, 95% CI: 47.23–57.60, RMST (CLNM ratio ≤0.111): 58.78m, 95% CI: 56.86–60.69, HR:5.873, respectively; Figures 2D, E). However, the cutoff points of age (>42 years and ≤ 42 years) did not have statistical differences for recurrence ($p = 0.24$; HR: 0.952, 95% CI: 0.892–1.016; Figure 2C). The RFS was significantly lower for the patients of metastasis nodes for CND ≥ 3 ($p = 0.035$, RMST (MNCND[+]): 48.04 m, 95% CI: 38.84–57.24, RMST (MNCND[−])= 58.15 m, 95% CI: 56.25–60.04, HR: 5.92; Figure 2F).

### TABLE 3 Characteristics of the patients with tumor recurrence.

| Patient # no. | Age, y | Sex | Size, mm | CLNM (%) | Multifocality | Extrathyroidal extension | Time to disease free survival, m | Recurrence site |
|---------------|--------|-----|----------|-----------|---------------|------------------------|-------------------------------|----------------|
| 1             | 29     | F   | 3        | 25%       | -             | +                      | 2                             | Level VI lymph node |
| 2             | 43     | M   | 5        | 0%        | +             | -                      | 50                            | Level III lymph node |
| 3             | 34     | F   | 3        | 25%       | +             | -                      | 18                            | Level III lymph node |
| 4             | 30     | M   | 8        | 54%       | +             | +                      | 17                            | Level II, III lymph node |
| 5             | 32     | M   | 7        | 100%      | -             | -                      | 17                            | Level IV lymph node |
| 6             | 51     | F   | 10       | 63%       | -             | +                      | 4                             | Level III lymph node |
| 7             | 31     | F   | 8        | 13%       | -             | -                      | 32                            | Level III lymph node |
| 8             | 38     | M   | 7        | 13%       | +             | +                      | 35                            | Level III, IV lymph node |
| 9             | 43     | F   | 6        | 43%       | -             | +                      | 7                             | Level II, III lymph node |

CLNM, Central lymph node metastases. + represents multifocal carcinoma or positive for Extrathyroidal extension. - Represents unifocal carcinoma or no Extrathyroidal extension.
The studies from the past 5 years have demonstrated that an increasing number of PTCs are being identified, which is based largely on an expansion in the use of diagnostic imaging and surveillance. Generally, most PTCs have an indolent course and an excellent outcome, with a 10-year RFS of 98% and 20-year cause-specific mortality rate of <1% (13, 14). PTCs arising in the thyroid isthmus have been reported in approximately 2.2–12.3% of all PTCs (4, 5). However, iPTCs may have a higher incidence of extrathyroidal invasion, CLNM, and multifocality than PTCs in the lateral lobes, because even a small tumor abuts the trachea and the thyroid capsule (15–18). J. Seok et al. observed that the presence of extrathyroidal extension of iPTC was 73.0%, which is significantly higher compared with PTCs in other sites (57.1%) (16). In the study of Song et al., the rate of CLNM of iPTCs was

### Discussion

The studies from the past 5 years have demonstrated that an increasing number of PTCs are being identified, which is based largely on an expansion in the use of diagnostic imaging and surveillance. Generally, most PTCs have an indolent course and an excellent outcome, with a 10-year RFS of 98% and 20-year cause-specific mortality rate of <1% (13, 14). PTCs arising in the thyroid isthmus have been reported in approximately 2.2–12.3% of all PTCs (4, 5). However, iPTCs may have a higher incidence of extrathyroidal invasion, CLNM, and multifocality than PTCs in the lateral lobes, because even a small tumor abuts the trachea and the thyroid capsule (15–18). J. Seok et al. observed that the presence of extrathyroidal extension of iPTC was 73.0%, which is significantly higher compared with PTCs in other sites (57.1%) (16). In the study of Song et al., the rate of CLNM of iPTCs was
71.1%, higher than that of other PTCs (40.3%) (18). Goldfarb et al. found that the proportion of multifocality was 48.6%, which was higher than in the lobes (39.8%) (6).

At present, there are no clear surgical guidelines for iPTCs, and the focus of debate is mainly on the extent of primary tumor resection. There are no specific guidelines for management of thyroid cancers confined to the thyroid isthmus. Several surgeons recommend that total thyroidectomy could be considered as an appropriate surgical treatment for PTC originating in the isthmus regardless of primary tumor size (6, 7). Only a few studies advocated isthmusectomy or wide field isthmusectomy as a suitable and reasonable surgical procedure for selected patients with small differentiated thyroid cancer limited to the isthmus without lymph node metastasis (8, 19, 20). Although the optimal extent of surgery for PTMC remains unclear, total thyroidectomy reduces tumor recurrence rates in patients with multifocal disease (21). In the current study, the rate of extrathyroidal extension and multifocality of iPTMC was 23.5% and 31.4%, respectively. Therefore, careful ultrasound evaluation should be performed in other sites of thyroid on iPTMCs preoperative for surgical decision-making (5).

The isthmus is located in front of the trachea and, due to its anatomical uniqueness, iPTCs may be detected early. Compared with PTC in other sites, iPTC tended to be smaller in size and had a higher proportion of multifocality was 48.6%, which was higher than in the lobes (39.8%) (6).

TABLE 5 Univariate and Multivariate Analysis of Variables Associated with tumor recurrence.

| Variables          | Univariate HR(95% CI) | p value | Multivariate HR(95% CI) | p value |
|--------------------|-----------------------|---------|-------------------------|---------|
| Sex, male          | 1.789 (0.927-3.452)   | 0.083   |                         |         |
| Age, ≥55 years     | 0.038 (0.000-86.587)  | 0.407   |                         |         |
| Tumor size, >5 mm  | 0.770 (0.192-3.082)   | 0.712   |                         |         |
| CLNM               | 4.812 (0.996-23.258)  | 0.051   |                         |         |
| Multifocality      | 1.608 (0.432-5.993)   | 0.479   |                         |         |
| Extrathyroidal extension | 4.351 (1.167-16.214) | 0.028   | 3.173 (0.820-12.272)    | 0.094   |
| ≥3 metastasis nodes for CND | 5.880 (1.578-21.913) | 0.008   | 4.566 (1.181-17.657)    | 0.028   |

CLNM, Central lymph node metastases; CND, Central neck dissection.

FIGURE 2
Recurrence-free survival according to tumor size (≤5 mm and >5 mm) (A), presence of extrathyroidal extension (B), age (≤42y and >42y) (C), CLNM (D), CLNM ratio (≤0.111 and >0.111) (E) and the number of metastatic lymph nodes (≥2 and ≤2) (F) in iPTMC. The Kaplan–Meier method for recurrence with the log-rank test was used for statistical comparisons of A–C. The restricted mean survival time (RMST) was used for survival analysis of D–F. CLNM, central lymph node metastasis.
of multifocality and CLNM were significantly lower in the ≤5 mm than in the >5 mm group. Female patients of iPTMC ≤5 mm were higher than that in the >5 mm. However, there were no statistically significant differences in extrathyroidal extension and TNM stage. Although male sex, lymph node metastasis, and multifocality are associated with poorer prognosis (30, 31), there were no significant differences in recurrence between the two groups. With a median follow-up of 49.5 months, the RFS of iPTMCs ≤5 mm and >5 mm did not have statistical differences. Time-dependent ROC analysis was conducted to clarify the cutoff point of tumor diameter in the current study. However, there were no statistically significant differences for recurrence.

On the study of Luo et al., tumor size of iPTC >11 mm was significantly associated with lymph node metastasis (23). Wang et al. found that tumor size >7 mm was associated with CLNM (32). Our findings revealed that the incidence of lymph node metastasis was significant high (52.1%) in iPTMC >5 mm group. However, the incidence of CLNM was relatively high in iPTMC >5 mm group when age <55 years, male sex, multiple tumor, and extrathyroidal extension existing showing no significant difference to that of same clinicopathologic factors in iPTMC ≤5 mm group. Therefore, we can infer that when the size of iPTMC is >5 mm, relatively high incidence of lymph node metastasis may occur when reaches certain risk factors. In fact, the correlation between lymph node metastasis and tumor recurrence was reported to be significant. CLNM was considered to be an aggressive clinical feature of PTMC related to higher incidence of recurrence (30, 31, 33). In the present study, the Kaplan–Meier survival analyses indicated that the RFS was better for iPTMCs without CLNM compared with that with CLNM. Of the nine cases of recurrence, one (11.1%) recurrence in a level VI lymph nodes and eight (88.9%) recurrences in lateral neck lymph nodes. Level III lymph nodes metastases accounted for 77.7% of all relapse cases.

With the comparison of clinicopathological variables of patients with and without recurrence, the relapse cases were found to be a higher CLNM (77.8%) and higher numbers of metastasis lymph nodes (p = 0.02). Several studies have found that the risk of recurrence was positively associated with a higher number of lymph nodes metastases at initial surgical operation (34, 35). The presence of >5 metastatic lymph nodes was associated with a significantly worse RFS than patients with <5 metastatic lymph nodes (36, 37). Interestingly, the present study shows that the presence of more than two metastatic lymph nodes is also associated with a significantly worse RFS. Using the existing data of iPTMC, we performed ROC curve analysis between the number of CLNM and recurrence. The AUC value was 0.729, cutoff value was 2.46, sensitivity was 55.6%, and specificity was 86.0%. The Kaplan–Meier survival analyses also indicated the significant differences of RFS between patients with ≥3 and <3 metastatic lymph nodes (p = 0.003). Furthermore, Cox proportional hazards model was used to identify risk factors for recurrence. On univariate analysis, risk factors for recurrence were extrathyroidal extension and ≥3 MNCND. Multivariate analysis indicated that the only independent risk factor for recurrence was ≥3 MNCND (HR, 4.566; 95% confidence interval, 1.18–17.66; p = 0.028). This showed that the model has a certain function in predicting recurrence and help clinicians for the decision of radioiodine administration and the modulation of follow-up modalities.

Our present study had several limitations. First, the sample size of the iPTMC was relatively small, which may cause a selection bias. Second, a relatively short follow-up time may be potential biases affecting the risk factor analyses and results. The retrospective nature of our study may also have led to selective bias. The larger number of patients with a longer period of follow-up is needed to overcome these limitations.

Conclusions

In conclusion, our findings demonstrate that the recurrence rates are similar in patients with iPTMCs ≤5 mm and >5 mm. Nonetheless, iPTMCs >5 mm was more likely to be associated with pathological features such as multifocality and CLNM. Higher risk of CLNM should be considered in evaluation and surgical decision of iPTMC >5 mm when reaches some risk factors. The male gender, extrathyroidal extension, and CLNM were associated with recurrence of iPTMCs except for multifocality. The numbers of metastasis nodes for CND ≥3 may be an independent predictor for recurrence, which could help clinicians for the decision of radioiodine administration and the modulation of follow-up modalities.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

FZ, and YW conceived the idea and designed the research. XX and FL collected data and followed up patients. FZ, LZ and YS participated in statistical analysis and article writing. All authors contributed to the article and approved the submitted version.
Funding

This work was supported by Zhejiang medical science and technology projects [2022KY786].

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol (2020) 16(1):17–29. doi: 10.1038/s41574-019-0265-z
2. Cramer JD, Fu P, Harth KC, Margercius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery (2010) 148(6):1147–52. doi: 10.1016/j.surg.2010.10.016
3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA (2006) 295(18):2164–7. doi: 10.1001/jama.295.18.2164
4. Hahn SY, Han BK, Ko EY, Shin JH, Ko ES. Ultrasonic findings of papillary thyroid carcinoma originating in the isthmus: Comparison with lobe-originating papillary thyroid carcinoma. J Am J Roentgenol (2014) 203(3):637–42. doi: 10.2214/AJR.13.10746
5. Lim ST, Jeon YW, Suh VJ. Correlation between surgical extent and prognosis in node-negative, early-stage papillary thyroid carcinoma originating in the isthmus. World J Surg (2016) 40(2):344–9. doi: 10.1007/s00268-015-3259-2
6. Lee YS, Jeong JJ, Nam KH, Chung WY, Chang HS, Park CS. Papillary carcinoma located in the thyroid isthmus. World J Surg (2010) 34(1):36–9. doi: 10.1007/s00268-009-0298-6
7. Karatzas T, Chatzidoudis G, Vasileiadis D, Kapetanakis S, Vasileiadis I. Surgical treatment for dominant malignant nodules of the isthmus of the thyroid gland: A case control study. Int J Surg (2015) 18:64–8. doi: 10.1016/j.ijsu.2015.04.039
8. Nixon JJ, Palmer FL, Whitcher MM, Shaha AR, Shah JP, Patel SG, et al. Thyroid isthmusectomy for well-differentiated thyroid cancer. Ann Surg Oncol (2011) 18(3):767–70. doi: 10.1245/s10434-010-1358-8
9. Bradley NL, Wiseman SM. Papillary thyroid microcarcinoma: The significance of high risk features. BMC Cancer (2017) 17(1):142. doi: 10.1186/s12885-017-3120-0
10. Lombardi CP, Bellantone R, Doherty GM, Mandel SJ, Alexander EK. Thyroidectomy in patients with thyroid microcarcinoma: A basic review. J Clin Endocrinol Metab (2013) 98(4):1427–34. doi: 10.1210/jc.2012-2372
11. Malandrino P, Pellegriti G, Attard M, Violi MA, Giordano C, Sciacca L, et al. Papillary thyroid microcarcinoma: A comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab (2013) 98(9):3599–607. doi: 10.1210/jc.2013-2573
12. Wada N, Duh QY, Sugino K, Ikawa K, Kamiyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: Frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg (2003) 237(3):399–407. doi: 10.1097/00000527-200306000-00019
13. Nixon JJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM. Treatment of thyroid cancer: 2007—a basic review. Int J Radiat Oncol Biol Phys (2007) 69(2 Suppl):S92–7. doi: 10.1016/j.ijrobp.2007.06.027
14. Vasileiadis I, Boutzios G, Karalki M, Musiakos E, Karatzas T. Papillary thyroid carcinoma of the isthmus: Total thyroidec tomy or isthmusectomy? Ann Surg (2018) 261(3):135–9. doi: 10.1097/01.amsj.2017.09.008
15. Seok J, Choi JY, Yu HW, Jung YH, Ahn SH, Jeong WJ. Papillary thyroid cancers of the thyroid isthmus: The pattern of nodal metastasis and the significance of extrathyroidal extension. Ann Surg Oncol (2020) 27(6):1937–44. doi: 10.1245/s10434-020-08215-0
16. So YK, Kim MW, Son YI. Multifocality and bilaterality of papillary thyroid microcarcinoma. Clin Exp Otorhinolaryngol (2015) 8(2):174–8. doi: 10.3342/ceo.2015.8.2.174
17. Song CM, Lee DW, Ji YB, Jeong JH, Park IH, Tae K. Frequency and pattern of central lymph node metastasis in papillary carcinoma of the thyroid isthmus. Head Neck (2016) 38 Suppl 1:E412–6. doi: 10.1002/hed.24009
18. Sugiyama A, Shingu K, Kobayashi S, Mavada H, Takahashi S, Shimizu T, et al. Surgical strategies for differentiated carcinoma of the thyroid isthmus. Head Neck (1993) 15(2):158–60. doi: 10.1002/hed.2880150212
19. Campenni A, Piantanida R, Giovannella L. Is ishmic envelope-resection a reliable treatment for ishmic differentiated thyroid carcinoma? A note of caution. J Endocrinol Invest (2020) 43(12):E1289–30. doi: 10.1007/s40618-020-01289-3
20. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 19(10):1043–8. doi: 10.1089/thy.2008.0407
21. Lyu YS, Pyo JS, Cho WJ, Kim SY, Kim JH. Clinicopathological significance of papillary thyroid carcinoma located in the isthmus: A meta-analysis. World J Surg (2021) 45(9):2759–68. doi: 10.1007/s00268-021-06178-1
22. Luo H, Yan F, Lan L, Ma B, Zhao H, He Y, et al. Ultrasoundographic features, nodule size, capsular invasion, and lymph node metastasis of solitary papillary carcinoma of thyroid isthmus. Front Oncol (2020) 10:558363. doi: 10.3389/fonc.2020.558363
23. Gui Z, Wang Z, Xiang J, Sun W, He L, Dong W, et al. Comparison of outcomes following thyroid isthmusectomy, unilateral thyroid lobectomy, and total thyroidec tomy in patients with papillary thyroid microcarcinoma of the thyroid isthmus: A retrospective study at a single center. Med Sci Monit (2020) 26:e927407. doi: 10.12659/MSM.927407
24. Lin JD. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Med Oncol (2016) 29(4):510–8. doi: 10.1007/s12032-016-0924-2
25. Liu Z, Wang L, Yi P, Wang CY, Huang T. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: A meta-analysis. Int J Clin Exp Pathol (2014) 7(3):932–7.
26. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nádolski YE, et al. American Thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer guidelines task force. JAMA (2015) 313(11):1133. doi: 10.1001/jama.2015.0020
27. Lee HS, Park HS, Kim SW, Choi G, Park HS, Hong JC, et al. Clinical characteristics of papillary thyroid microcarcinoma less than or equal to 5 mm on ultrasonography. Eur Arch Otorhinolaryngol (2013) 270(11):2969–74. doi: 10.1007/s00405-013-2634-6
28. Kim E, Choi JY, Koo do H, Lee KE, Youn YK. Differences in the characteristics of papillary thyroid microcarcinoma <5 mm and >5 mm in diameter. Head Neck (2015) 37(5):694–7. doi: 10.1002/hed.23654
29. Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg (2011) 254(4):653–60. doi: 10.1097/SLA.0b013e318200363d
30. Hay JD, Hutchinson ME, Gonzalez-Losada T, McVber R, Reinalde ME, Grant CS, et al. Papillary thyroid microcarcinoma: A study of 900 cases

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
observed in a 60-year period. Surgery (2008) 144(6):980–7. doi: 10.1016/j.surg.2008.08.035

32. Wang J, Sun H, Gao L, Xie L, Cai X. Evaluation of thyroid isthmusectomy as a potential treatment for papillary thyroid carcinoma limited to the isthmus: A clinical study of 73 patients. Head Neck (2016) 38 Suppl 1:E1510–4. doi: 10.1002/hed.24270

33. Ardito G, Avenia N, Giustozzi E, Salvatori M, Fadda G, Ardito F, et al. Papillary thyroid microcarcinoma: Proposal of treatment based on histological prognostic factors evaluation. Ann Ital Chir (2014) 85(1):1–5.

34. Leboulleux S, Rubino C, Basdin E, Cailou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab (2005) 90(10):5723–9. doi: 10.1210/jc.2005-0285

35. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kohayashi K, et al. Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years. Surg Today (2006) 36(1):12–8. doi: 10.1007/s00595-005-3090-8

36. Ito Y, Fukushima M, Tomoda C, Inoue H, Kihara M, Higashiyama T, et al. Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment. Endocr J (2009) 56(6):759–66. doi: 10.1507/endocrj.k09e-025

37. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid (2012) 22(11):1144–52. doi: 10.1089/thy.2012.0043